COMPANY PROFILE

Biointron

Explore full profile

High-throughput antibody expression and discovery CRO

Pudong, ChinaFounded 2012Biotech & Life Sciences

Valuation $250–500M Last recorded · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Biointron

Biointron (百英生物) is a Shanghai antibody CRO founded in 2012 specializing in high-throughput recombinant antibody expression (gene-to-purified antibody in about one week), antibody discovery and optimization including nanobody, single-B-cell and affinity-maturation platforms, plus ADC conjugation support. Headquarters is in Zhoupu, Pudong, Shanghai, with a Taizhou manufacturing center. The company serves 3,000+ biopharma clients across 20+ countries.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Pudong, China
Employees: 40
Open positions: None listed
Dealroom signal: 47.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Aug 2022	$69M	$275M	Joy Capital · Jiangsu Tech Industry Investment · Xishanghai Jituan · Gaorong Capital	↗
SERIES AOther financing	Jul 2021	$0	—	CS Capital	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Biointron website traffic

Latest recorded traffic for Biointron is 47K monthly website visits, up 38.2% over the last three months. Biointron's team grew 5.3% over the past year.

Latest monthly visits47K 3-month web change+38.2% 1-year team growth+5.3%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNerio TherapeuticsNerio is building a new generation of therapeutics targeting protein phosphatases for immunotherapy	San Diego, United States	Acquired	—	$3.5M	$1.3B
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
JLJunhe LeagueRecombinant protein drug developer	Hangzhou, China	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
BTBiolexis TherapeuticsReimagines drug discovery with it's proprietary FIELDS Technology	Sandy, United States	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
PBProtai BioIlluminating the druggable Proteome for better cures	Tel Aviv-Yafo, Israel	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed